Skip to main content
. 2016 Aug 11;7(40):65185–65195. doi: 10.18632/oncotarget.11218

Figure 1. The design flow of this cohort study.

Figure 1

The three study populations and subsets analyzed are shown. TKIs, tyrosine kinase inhibitors. PFS, progression-free survival. OS, overall survival. ORR, objective response rate.EGFR, epidermal growth factor receptor.ALK, anaplastic lymphoma kinase.